Semaglutide Slows HIV Aging Markers by 9% in 108-Adult Randomized Trial
Updated
Updated · University of California · Jun 12
Semaglutide Slows HIV Aging Markers by 9% in 108-Adult Randomized Trial
3 articles · Updated · University of California · Jun 12
Summary
A 32-week randomized, placebo-controlled trial in 108 adults with HIV-linked lipohypertrophy found semaglutide slowed biological aging pace by 9% on the DunedinPACE epigenetic clock.
Nature Communications researchers also reported slower aging signals across clocks tied to inflammation and blood, brain, heart, kidney, liver and metabolic health, including measures linked to all-cause mortality risk.
The study points to reduced inflammation, lower metabolic stress and less visceral fat as likely drivers in people with HIV, who often show accelerated aging despite antiretroviral treatment.
A separate 24-week pilot study published last month found semaglutide reduced aging rates in 42% of participants with HIV and fatty liver disease, while nearly 49% showed longer telomeres.
Researchers said the findings do not show age reversal and still require larger trials to confirm durability, dosing and whether benefits extend to broader populations.
How can we predict who will benefit from this drug's anti-aging effects when 10% are genetically resistant?
Is semaglutide a true anti-aging drug, or do its benefits just come from weight loss and reduced inflammation?
Semaglutide Reduces Biological Aging Markers by 9%: Breakthrough Clinical Trial in HIV-Associated Lipohypertrophy
Overview
A major clinical trial led by the University of California, San Diego, and published in June 2026, found that weekly semaglutide injections over 32 weeks significantly slowed biological aging in adults with HIV-associated lipohypertrophy, a group known for accelerated aging. The study used advanced DNA methylation-based epigenetic clocks to measure aging and showed that semaglutide reduced the pace of aging by 9% and improved key markers like PCGrimAge. The most notable benefits were seen in measures linked to systemic inflammation and the health of organs such as the blood, brain, heart, kidney, liver, and metabolic systems.